This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

No specific pharmacological effects mentioned

Antipyretic analgesic, mainly produces analgesic effect by inhibiting prostaglandin synthesis

Nausea expectorant, which stimulates the gastric mucosa to cause mild nausea, which reflexively increases the secretion of respiratory glands, dilutes sputum and makes it easier to cough up

Adrenaline-mimetic drugs can constrict the blood vessels of the nasal mucosa and relieve symptoms of nasal congestion and runny nose

Central antitussive drugs can inhibit the cough center in the medulla oblongata to produce an antitussive effect. Generally, the therapeutic dose does not inhibit breathing, and long-term use is non-addictive and non-tolerant.

No specific pharmacological information is provided

Not described in detail